Cisatracurium
Nimbex (cisatracurium) is a small molecule pharmaceutical. Cisatracurium was first approved as Nimbex on 1995-12-15.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Nimbex (generic drugs available since 2012-02-03)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cisatracurium besylate | ANDA | 2023-02-26 |
| nimbex | New Drug Application | 2019-10-25 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
112 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Intermittent claudication | D007383 | EFO_0003876 | I73.9 | 5 | 2 | — | 1 | 2 | 10 |
| Coronary artery disease | D003324 | I25.1 | — | — | 1 | 7 | 1 | 9 | |
| Peripheral arterial disease | D058729 | EFO_0004265 | 1 | 1 | 1 | 4 | 1 | 8 | |
| Healthy volunteers/patients | — | 7 | — | — | 1 | — | 8 | ||
| Cerebral infarction | D002544 | I63 | — | — | 2 | 6 | — | 8 | |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | 7 | — | 7 |
| Cerebral small vessel diseases | D059345 | 1 | 3 | 1 | 1 | — | 4 | ||
| Ischemic stroke | D000083242 | — | — | — | 3 | — | 3 | ||
| Acute coronary syndrome | D054058 | EFO_0005672 | — | — | — | 3 | — | 3 | |
| Stroke | D020521 | EFO_0000712 | I63.9 | 1 | 1 | — | 1 | — | 3 |
Show 27 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | 1 | 2 | — | — | 2 |
| Coronary stenosis | D023921 | EFO_1000882 | — | — | 1 | — | — | 1 | |
| Cerebrovascular disorders | D002561 | EFO_0003763 | I60-I69 | — | — | 1 | — | — | 1 |
| Lacunar stroke | D059409 | I63.81 | — | 1 | 1 | — | — | 1 | |
| Vestibuloplasty | D014727 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cognitive dysfunction | D060825 | G31.84 | — | 2 | — | — | 1 | 3 | |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | 1 | 1 | — | — | — | 1 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 1 | 1 | — | — | — | 1 |
| Leukoencephalopathies | D056784 | HP_0002352 | R90.82 | 1 | 1 | — | — | — | 1 |
| Cadasil | D046589 | Orphanet_136 | I67.850 | 1 | 1 | — | — | — | 1 |
| Contraception | D003267 | — | 1 | — | — | — | 1 | ||
| Heart failure | D006333 | EFO_0003144 | I50 | — | 1 | — | — | — | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | — | — | — | 1 |
| Peripheral nervous system diseases | D010523 | G64 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Migraine with aura | D020325 | EFO_0005295 | G43.1 | 1 | — | — | — | 1 | 2 |
| Dyslipidemias | D050171 | HP_0003119 | 1 | — | — | — | — | 1 | |
| Pain | D010146 | EFO_0003843 | R52 | 1 | — | — | — | — | 1 |
| Therapeutic equivalency | D013810 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | — | — | — | 5 | 5 |
| Migraine without aura | D020326 | EFO_0005296 | G43.0 | — | — | — | — | 2 | 2 |
| Coronary disease | D003327 | — | — | — | — | 1 | 1 | ||
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | — | — | 1 | 1 |
| Tinnitus | D014012 | HP_0000360 | H93.1 | — | — | — | — | 1 | 1 |
| Post-traumatic headache | D051298 | G44.3 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | CISATRACURIUM |
| INN | cisatracurium besilate |
| Description | Cisatracurium besylate is the (1R,1'R,2R,2'R)-diastereoisomer of atracurium besylate. Commercial preparations of atracurium are mixtures of 10 stereoisomers, of which cisatracurium generally constitutes about 15%. Cisatracurium besylate is about 3 times more potent than the mixture of atracurium isomers as a neuromuscular blocking agent, and is used as a muscle relaxant for endotracheal intubation, to aid controlled ventilation, and in general anaesthesia. It has a role as a muscle relaxant and a nicotinic antagonist. It is a quaternary ammonium salt, an atracurium besylate and an organosulfonate salt. It contains a cisatracurium. |
| Classification | Small molecule |
| Drug class | quaternary ammonium derivatives: neuromuscular blocking agents |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC |
Identifiers
| PDB | — |
| CAS-ID | 96946-41-7 |
| RxCUI | 136561 |
| ChEMBL ID | CHEMBL1201248 |
| ChEBI ID | — |
| PubChem CID | 62886 |
| DrugBank | DB00565 |
| UNII ID | 80YS8O1MBS (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,484 documents
View more details
Safety
Black-box Warning
Black-box warning for: Cisatracurium besylate
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,103 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more